Risk of major liver resection in patients with underlying chronic liver disease - A reappraisal

被引:262
作者
Farges, O
Malassagne, B
Flejou, JF
Balzan, S
Sauvanet, A
Belghiti, J
机构
[1] Univ Paris 07, Serv Chirurg, Beaujon Hosp, Dept Hepatobiliary & Digest Surg, F-92118 Clichy, France
[2] Univ Paris 07, Beaujon Hosp, Dept Pathol, Clichy, France
关键词
D O I
10.1097/00000658-199902000-00008
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective To explore the relation of patient age, status of liver parenchyma, presence of markers of active hepatitis, and blood loss to subsequent death and complications in patients undergoing a similar major hepatectomy for the same disease using a standardized technique. Summary Background Data Major liver resection carries a high risk of postoperative liver failure in patients with chronic liver disease. However, this underlying liver disease may comprise a wide range of pathologic changes that have, in the past, not been well defined. Methods The nontumorous liver of 55 patients undergoing a right hepatectomy for hepatocellular carcinoma was classified according to a semiquantitative grading of fibrosis. The authors analyzed the influence of this pathologic feature and of other preoperative variables on the risk of postoperative death and complications. Results Serum bilirubin and prothrombin time increased on postoperative day 1, and their speed of recovery was influenced by the severity of fibrosis. Incidence of death from liver failure was 32% in patients with grade 4 fibrosis (cirrhosis) and 0% in patients with grade 0 to 3 fibrosis. The preoperative serum aspartate transaminase (ASAT) level ranged from 68 to 207 IU/I in patients with cirrhosis who died, compared with 20 to 62 in patients with cirrhosis who survived. Conclusion A major liver resection such as a right hepatectomy may be safely performed in patients with underlying liver disease, provided no additional risk factors are present. Patients with a preoperative increase in ASAT should undergo a liver biopsy to rule out the presence of grade 4 fibrosis, which should contraindicate this resection.
引用
收藏
页码:210 / 215
页数:6
相关论文
共 21 条
  • [1] Belghiti J, 1998, J Hepatobiliary Pancreat Surg, V5, P69, DOI 10.1007/PL00009953
  • [2] INTRAHEPATIC RECURRENCE AFTER RESECTION OF HEPATOCELLULAR-CARCINOMA COMPLICATING CIRRHOSIS
    BELGHITI, J
    PANIS, Y
    FARGES, O
    BENHAMOU, JP
    FEKETE, F
    [J]. ANNALS OF SURGERY, 1991, 214 (02) : 114 - 117
  • [3] RESULTS OF MAJOR HEPATECTOMY FOR LARGE PRIMARY LIVES CANCER IN PATIENTS WITH CIRRHOSIS
    CAPUSSOTTI, L
    BORGONOVO, G
    BOUZARI, H
    SMADJA, C
    GRANGE, D
    FRANCO, D
    [J]. BRITISH JOURNAL OF SURGERY, 1994, 81 (03) : 427 - 431
  • [4] Caselmann WH, 1996, J HEPATOL, V24, P61
  • [5] CHUNG C, 1996, SURGERY, V120, P34
  • [6] FAN ST, 1995, ARCH SURG-CHICAGO, V130, P198
  • [7] Hepatectomy with an ultrasonic dissector for hepatocellular carcinoma
    Fan, ST
    Lai, ECS
    Lo, CM
    Chu, KM
    Liu, CL
    Wong, J
    [J]. BRITISH JOURNAL OF SURGERY, 1996, 83 (01) : 117 - 120
  • [8] HASEGAWA H, 1985, TUMORI FEGATO, P155
  • [9] FORMULATION AND APPLICATION OF A NUMERICAL SCORING SYSTEM FOR ASSESSING HISTOLOGICAL ACTIVITY IN ASYMPTOMATIC CHRONIC ACTIVE HEPATITIS
    KNODELL, RG
    ISHAK, KG
    BLACK, WC
    CHEN, TS
    CRAIG, R
    KAPLOWITZ, N
    KIERNAN, TW
    WOLLMAN, J
    [J]. HEPATOLOGY, 1981, 1 (05) : 431 - 435
  • [10] MATSUMATA T, 1994, HEPATO-GASTROENTEROL, V41, P165